SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community leans into its established two-year Solana history, using persistent meme-driven engagement and organic social promotion to rally holders. Investors are actively discussing the token's presence on the Jupiter strict list and its role within the broader meme coin meta, with discussions centered on whale accumulation and long-term community dedication.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as a nostalgic yet serious cultural movement, leveraging its 2011 origin as the internet's original Bitcoin parody to capture investor attention. The community is actively highlighting its deep historical roots, recent high-profile whale endorsements, and its transition onto modern blockchain infrastructure as key factors driving its momentum.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

The TRUMP meme coin is facing severe downward pressure and community backlash, with investors reacting to allegations of a "pump and dump" scheme and frustration over the coin's utility following recent high-profile events. The conversation is dominated by intense political polarization, with critics citing the coin as part of a broader pattern of financial exploitation while supporters continue to debate its role as a speculative asset.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining significant traction as traders weigh a major expansion to the Ethereum mainnet alongside strong institutional accumulation and consistent protocol revenue growth. The community is actively discussing the token's role as a primary liquidity hub on the Base ecosystem, with many investors viewing current price action as a strategic accumulation opportunity ahead of anticipated market shifts.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

ORCA is experiencing a massive short squeeze following a significant uptick in trading volume and public attention related to its role in the Solana ecosystem. Community members are actively debating the token's explosive price action, with some focused on the potential for continued momentum while others caution against the volatility of this pump.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to the FDA lifting clinical holds on its key cardiovascular trial, fueling speculation about a potential short squeeze given the stock's elevated short interest. While the company faces pressure from macroeconomic volatility and dilution concerns, the community is focused on the long-term potential of its in vivo gene editing pipeline and upcoming pivotal trial data readouts.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing significant volatility as investors weigh strong earnings and sales growth against negative market sentiment surrounding a controversial Super Bowl advertisement. While some community members view the sharp price decline as an irrational reaction that creates a buying opportunity, others are debating whether the dip reflects broader concerns over valuation and consumer spending trends.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is trending as the community actively promotes UPDOG, highlighting its inclusion on the Jupiter Strict List and long-term presence on the Solana network. Investors are discussing the platform's utility, recent updates to its lending protocols, and community-driven efforts to increase project visibility.

TOSHI

TOSHI is trending as investors bet on the token's potential to lead a meme coin rally on the Base network, with community members actively discussing accumulation strategies and anticipating a major breakout. Conversations are dominated by bullish long-term holders, competitive comparisons to other meme projects, and optimism that increased trading volume will drive the asset toward significant price milestones.

Peanut the Squirrel Markets

Peanut the Squirrel is seeing significant volatility as the community remains divided between speculative optimism for a recovery toward previous highs and concerns over potential pump-and-dump dynamics. Discussions are heavily focused on the coin's ability to capitalize on broader crypto market momentum and its high-risk, high-reward nature relative to other meme assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Buy" by Brokerages

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has been assigned an average recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports...

<ul class="summary-bullets"><li>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors.</li><li>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for gross proceeds up to approximately $354 million.&nbsp;</li><li>Achieve is now looking forward to launching cytisinicline for nicotine dependence in the first half of 2027.</li></ul><p><br>Shares of Achieve Life Sciences Inc. (ACHV) gained 42% on Thursday after the company appointed a new CEO, shortly after announcing a private placement of up to $354 million, as it gears towards getting regulatory approval for its experimental drug for the treatment of nicotine dependence.</p><p>The stock is on track to clock its best day since February 2019, if gains hold.</p><h2 class="st-heading-2">New CEO, Board Appointments</h2><p>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors. Goldberg, who most recently served as a Portfolio Manager at Marshall Wace, will replace Richard Stewart as CEO.</p><p>The company also appointed Lucian Iancovici and Aaron E. Royston as members of the company’s board of directors.</p><h2 class="st-heading-2">Fresh Funding</h2><p>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities.</p><p>The placement includes an initial upfront funding of approximately $180 million and an additional amount of up to approximately $174 million on exercise of milestone-driven warrants. The net proceeds from the placement is expected to fund a clinical trial for cytisinicline for e-cigarette cessation, the commercialization of cytisinicline, and for working capital and general corporate purposes, the company said.</p><h2 class="st-heading-2">Near-Term Milestones</h2><p>Achieve is now looking forward to the U.S. Food and Drug Administration’s approval of cytisinicline as a treatment for nicotine dependence.</p><p>Earlier this week, the company said that it expects the FDA to reject its current application by June 20, provided that the agency found manufacturing concerns at its third-party manufacturing facility. Once the formal rejection is received, the company expects to resubmit its application naming &nbsp;Adare Pharma Solutions as its manufacturer for commercial supply in the fourth quarter of 2026, it said. The company continues to expect to launch cytisinicline in the first half of 2027.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around ACHV stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.</p><p>A Stocktwits user expressed optimism for the company getting acquired after approval for cytisinicline.</p><p><stembedurl>https://www.stocktwits.com/Biotech_Pharma_Investor/message/650482761</stembedurl></p><p>Another user expressed optimism for a good year following the “professional” announcements.</p><p><stembedurl>https://www.stocktwits.com/Sieppo/message/650471510</stembedurl></p><p><a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> has more than doubled over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/hubc-stock-tanks-after-massive-rally-reverse-split/cZJvo99RIDA">HUBC Stock Declines 35% After A Whopping Two-Day Rally – What’s Driving The Change In Momentum?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Achieve Life Sciences logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 

Equity

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 


Achieve Life Sciences' (ACHV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm...

What is Zacks Research's Estimate for ACHV FY2026 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Zacks Research dropped their FY2026 earnings per share estimates for shares of Achieve Life Sciences in a note issued to investors on...

HC Wainwright Has Positive Estimate for ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings estimates for shares of Achieve Life Sciences in a research report issued...

Achieve Life Sciences Flags FDA Observations While Pushing Launch To 2027 For Smoking Cessation Med

Achieve Life Sciences taps Adare for cytisinicline manufacturing as stock falls; reports wider losses and shifts US launch timeline to 2027.read more...

Q1 Earnings Estimate for ACHV Issued By HC Wainwright

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Achieve Life Sciences in a research report...

HC Wainwright Reiterates "Buy" Rating for Achieve Life Sciences (NASDAQ:ACHV)

HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective on shares of Achieve Life Sciences in a research report on Wednesday...

Achieve Life Sciences Sees Unusually Large Options Volume (NASDAQ:ACHV)

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 2,079 call options on the company. This represents an increase of approximately 175% compared to the typical daily volume of 756 call options...

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.30	--	--	N/A
Q4 '25	-$0.29	-$0.28	2.78%	BEAT
Q3 '25	-$0.24	-$0.28	-14.75%	MISSED
Q2 '25	-$0.37	-$0.37	-1.09%	MISSED
Q1 '25	-$0.38	-$0.37	3.06%	BEAT

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ACHV News

ACHVAchieve Life Sciences Inc.